News/Events
Subscribe to get latest news
News
Flamingo Therapeutics Announces Poster Presentation at ESMO Congress 2023
Flamingo Therapeutics (“Flamingo”) today announced the presentation of a “Trials-in-Progress”, or TiP, poster at the ESMO Congress 2023, taking place October 20-24, 2023, in Madrid, Spain.
Flamingo Therapeutics Announces Participation at Upcoming Investor and Industry Conferences
Flamingo Therapeutics (“Flamingo”) today announced that company management will participate at several upcoming investor and industry conferences in October 2023:
Flamingo Therapeutics Receives €1.7M Grant Award from VLAIO to Advance RNA-Targeting Oncology Portfolio
Flamingo Therapeutics (“Flamingo”) today announced that it has been awarded a research grant of €1.7 million by Flanders Innovation & Entrepreneurship (VLAIO). The award represents the funding at 60% of a €2.9 million project.
Flamingo Therapeutics Announces Poster Presentation on FTX-001 at the 2023 American Association for Cancer Research (AACR) Annual Meeting
Flamingo Therapeutics (“Flamingo”) today announced a presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023, in Orlando, Florida.
Flamingo Therapeutics Announces Appointment of Andrew E. Denker, MD, PhD, as Chief Medical Officer
Dr. Denker is a physician-scientist with over two decades of biotech and pharmaceutical industry experience in clinical development across multiple modalities and therapeutic areas, including oncology and rare disease.
Flamingo Therapeutics and Dynacure Announce Merger to Create Leading RNA Therapeutics Company Focused on Clinical Oncology
Flamingo Therapeutics (“Flamingo”) and Dynacure, announced today that the companies have signed a definitive merger agreement to combine their pipelines and expertise to create a leading oncology company.